benazepril and Cardiomyopathy--Hypertrophic

benazepril has been researched along with Cardiomyopathy--Hypertrophic* in 2 studies

Trials

1 trial(s) available for benazepril and Cardiomyopathy--Hypertrophic

Article	Year
Benazepril and subclinical feline hypertrophic cardiomyopathy: a prospective, blinded, controlled study. The Canadian veterinary journal = La revue veterinaire canadienne, 2006, Volume: 47, Issue:5 Twenty-one cats with hypertrophic cardiomyopathy were enrolled in this study to determine if the administration of benazepril (0.5 mg/kg body weight [BW], PO, q24h) to cats with subclinical hypertrophic cardiomyopathy improves cardiac diastolic function and reverses left ventricular hypertrophy when compared with diltiazem controlled delivery (CD) (10 mg/kg BW, PO, q24h). Cats were evaluated at day 0 and after 3 and 6 months of therapy. In the benazepril group (n = 11), the diastolic transmitral flow of the E and A waves ratio (E/A ratio) increased significantly between 0 and 6 months (P = 0.009) and the thickness of the left ventricular free wall in systole (LVFWs) decreased significantly between 0 and 3 months (P = 0.04). In the diltiazem CD group (n = 5), none of the parameters varied significantly throughout the study. There was no difference between the benazepril and the diltiazem CD group throughout the study. Therefore, the variations observed for the E/A ratio and the LVFWs may have been incidental. Further studies will be needed to establish the role of benazepril in subclinical hypertrophic cardiomyopathy in cat. Topics: Animals; Antihypertensive Agents; Benzazepines; Cardiomyopathy, Hypertrophic; Cat Diseases; Cats; Diltiazem; Double-Blind Method; Echocardiography; Female; Male; Prospective Studies; Treatment Outcome	2006

Article

Year

Benazepril and subclinical feline hypertrophic cardiomyopathy: a prospective, blinded, controlled study.

The Canadian veterinary journal = La revue veterinaire canadienne, 2006, Volume: 47, Issue:5

Twenty-one cats with hypertrophic cardiomyopathy were enrolled in this study to determine if the administration of benazepril (0.5 mg/kg body weight [BW], PO, q24h) to cats with subclinical hypertrophic cardiomyopathy improves cardiac diastolic function and reverses left ventricular hypertrophy when compared with diltiazem controlled delivery (CD) (10 mg/kg BW, PO, q24h). Cats were evaluated at day 0 and after 3 and 6 months of therapy. In the benazepril group (n = 11), the diastolic transmitral flow of the E and A waves ratio (E/A ratio) increased significantly between 0 and 6 months (P = 0.009) and the thickness of the left ventricular free wall in systole (LVFWs) decreased significantly between 0 and 3 months (P = 0.04). In the diltiazem CD group (n = 5), none of the parameters varied significantly throughout the study. There was no difference between the benazepril and the diltiazem CD group throughout the study. Therefore, the variations observed for the E/A ratio and the LVFWs may have been incidental. Further studies will be needed to establish the role of benazepril in subclinical hypertrophic cardiomyopathy in cat.

Topics: Animals; Antihypertensive Agents; Benzazepines; Cardiomyopathy, Hypertrophic; Cat Diseases; Cats; Diltiazem; Double-Blind Method; Echocardiography; Female; Male; Prospective Studies; Treatment Outcome

2006

Other Studies

1 other study(ies) available for benazepril and Cardiomyopathy--Hypertrophic

Article	Year
End-stage hypertrophic cardiomyopathy in a cat. The Canadian veterinary journal = La revue veterinaire canadienne, 2015, Volume: 56, Issue:5 A 14-year-old Persian cat was referred for evaluation of the progression of hypertrophic cardiomyopathy (HCM) after an acute episode of congestive heart failure. The diagnosis of HCM had been made almost 13 years ago. Echocardiography and electrocardiography revealed end-stage hypertrophic cardiomyopathy and multifocal atrial tachycardia. The patient was discharged on medical management with a grave prognosis. Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia Agents; Atenolol; Benzazepines; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cat Diseases; Cats; Clopidogrel; Diuretics; Furosemide; Male; Platelet Aggregation Inhibitors; Pyridazines; Ticlopidine	2015

Article

Year

End-stage hypertrophic cardiomyopathy in a cat.

The Canadian veterinary journal = La revue veterinaire canadienne, 2015, Volume: 56, Issue:5

A 14-year-old Persian cat was referred for evaluation of the progression of hypertrophic cardiomyopathy (HCM) after an acute episode of congestive heart failure. The diagnosis of HCM had been made almost 13 years ago. Echocardiography and electrocardiography revealed end-stage hypertrophic cardiomyopathy and multifocal atrial tachycardia. The patient was discharged on medical management with a grave prognosis.

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia Agents; Atenolol; Benzazepines; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cat Diseases; Cats; Clopidogrel; Diuretics; Furosemide; Male; Platelet Aggregation Inhibitors; Pyridazines; Ticlopidine

2015